Uncover key drivers, emerging technologies, and competitive movements shaping the irritable bowel syndrome (ibs) treatment market from 2026–2035 with trusted insights from The Business Research Company
What market expansion outlook does the Irritable Bowel Syndrome (IBS) Treatment Market show for the 2026–2030 period?
The irritable bowel syndrome (ibs) treatment market has experienced robust growth over the last few years. This market is projected to expand from $7.41 billion in 2025 to $7.97 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.6%. Historically, this expansion has been driven by factors such as an increase in gastrointestinal disorder prevalence, higher rates of ibs diagnosis, greater public awareness of digestive health, the widespread availability of prescription ibs medications, and the widening reach of hospital and retail pharmacy networks.
The irritable bowel syndrome (ibs) treatment market is poised for significant expansion over the next few years. It is projected to attain a size of $10.65 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.5%. This anticipated growth is influenced by advancements in precision medicine, the growing embrace of digital health platforms, the proliferation of online pharmacy channels, a concentrated effort on microbiome research, and increased healthcare spending for chronic conditions. Noteworthy trends during the forecast period encompass precision medicine and microbiome-based therapies, the incorporation of digital therapeutics and mobile health, AI-driven IBS diagnosis and treatment optimization, remote patient monitoring alongside smart gut health devices, and the development of sustainable, patient-centric drugs.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11978&type=smp
What Drivers Are Shaping The Development Of The Irritable Bowel Syndrome (IBS) Treatment Market?
The increasing occurrence of Irritable Bowel Syndrome (IBS) is anticipated to drive the expansion of the IBS treatment market in the future. IBS is a persistent gastrointestinal ailment impacting the large intestine, leading to symptoms like constipation, diarrhea, abdominal pain, and bloating, which considerably reduce life quality. The rise in IBS cases stems from lifestyle elements such as inadequate diet, stress, and environmental factors, contributing to more people acquiring the condition. The IBS treatment market addresses patient requirements through pharmacological solutions, including antispasmodics and gut-focused drugs, and non-pharmacological approaches like cognitive behavioral therapy, hypnotherapy, and dietary modifications. For example, in December 2023, the IBD Registry, a UK-based non-profit organization, reported engaging over 5,300 individuals with Inflammatory Bowel Disease (IBD) by 2023, marking an increase of over 3,000 members compared to 2022. Consequently, the growing prevalence of IBS is fueling the expansion of the IBS treatment market.
What Segment Types Are Examined In The Irritable Bowel Syndrome (IBS) Treatment Market?
The irritable bowel syndrome (ibs) treatment market covered in this report is segmented –
1) By Drug Type: Eluxadoline, Alosetron, Other Drugs
2) By Indication: IBS With Constipation, IBS With Diarrhea, IBS With Alternating Constipation And Diarrhea
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
4) By End-Users: Hospitals, Clinics, Homecare Settings
Subsegments:
1) By Eluxadoline: IBS with Diarrhea (IBS-D) Treatment, Moderate IBS-D Treatment
2) By Alosetron: Severe IBS-D Treatment for Women, Refractory IBS-D Treatment
3) By Other Drugs: Prucalopride, Tenapanor, Plecanatide
Which Trends Are Shaping Activity Within The Irritable Bowel Syndrome (IBS) Treatment Market?
Leading companies in the irritable bowel syndrome (IBS) treatment market are increasingly incorporating digital therapeutics, such as mobile applications utilizing gut-directed hypnotherapy, to enhance patient engagement, broaden treatment accessibility, and improve symptom management. These gut-directed hypnotherapy–based mobile applications serve as prescription digital platforms, delivering structured hypnotherapy sessions via smartphone interfaces to modulate gut–brain interaction. This technology provides capabilities including guided behavioral therapy, real-time symptom tracking, and automated monitoring of patient progress. For example, in May 2023, Launchit DTx, a Canada-based digital health commercialization company, introduced Regulora, a gut-directed hypnotherapy–based digital therapeutic developed to assist adults in managing abdominal pain associated with irritable bowel syndrome (IBS). Regulora features evidence-based hypnotherapy modules, clinician-enabled prescribing workflows, and a mobile app designed to track patient response over time. By offering a non-pharmacologic, digitally delivered therapeutic option, Regulora improves treatment access, supports self-management, and contributes to overall symptom relief for IBS patients.
Who Are The Major Companies Operating In The Irritable Bowel Syndrome (IBS) Treatment Market?
Major companies operating in the irritable bowel syndrome (ibs) treatment market are Ironwood Pharmaceuticals Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., Johnson & Johnson Services Inc., AstraZeneca plc, Novartis AG, Abbott Laboratories, Eli Lilly and Company, Astellas Pharma Inc., Bausch Health Companies Inc., Sebela Pharmaceuticals Inc., Prometheus Laboratories Inc., RedHill Biopharma Ltd., Ardelyx Inc., Renexxion Ireland Ltd., 4D Pharma plc, Biora Therapeutics Inc., Salix Pharmaceuticals Ltd., Allergan plc, Synergy Pharmaceuticals Inc.
Access The Complete Report For Deeper Market Insights:
Which Region Is Anticipated To See The Fastest Growth In The Irritable Bowel Syndrome (IBS) Treatment Market?
North America was the largest region in the irritable bowel syndrome (IBS) treatment market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the irritable bowel syndrome (ibs) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Irritable Bowel Syndrome (IBS) Treatment Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=11978&type=smp
Browse Through More Reports Similar to the Global Irritable Bowel Syndrome (IBS) Treatment Market 2026, By The Business Research Company
Constipation Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/constipation-treatment-global-market-report
Inflammatory Bowel Disease Treatment Market Report 2026
Bowel Management Systems Market Report 2026
https://www.thebusinessresearchcompany.com/report/bowel-management-systems-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model